# EDGAR Filing Document

**Accession Number:** 0001719406
**File Stem:** 0001437749-25-038319
**Filing Date:** 2025-12
**Character Count:** 2428
**Document Hash:** 15bbe9dbcd1aab4023fcb5e3ae1cf29e
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001437749-25-038319.hdr.sgml**: 20260616

**ACCESSION NUMBER**: 0001437749-25-038319

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20251218

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** NRX Pharmaceuticals, Inc.
- **CENTRAL INDEX KEY:** 0001719406
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 822844431
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** 1201 ORANGE STREET
- **STREET 2:** SUITE 600
- **CITY:** WILMINGTON
- **STATE:** DE
- **ZIP:** 19801
- **BUSINESS PHONE:** 484-254-6134

**MAIL ADDRESS:**
- **STREET 1:** 1201 ORANGE STREET
- **STREET 2:** SUITE 600
- **CITY:** WILMINGTON
- **STATE:** DE
- **ZIP:** 19801

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Big Rock Partners Acquisition Corp.
- **DATE OF NAME CHANGE:** 20171012

**NRx Pharmaceuticals, Inc.**<br> **1201 Orange Street, Suite 600**<br> **Wilmington, DE 19801**

December 18, 2025

**<u>VIA EDGAR</u>**

United States Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

Attention: Jason Drory

---

| | |
|:---|:---|
| **Re:** | **NRx Pharmaceuticals, Inc.** <br> **Registration Statement on Form S-3/A**<br> **File No. 333-288205**<br> **Request for Effectiveness** |

---

Dear Mr. Drory:

Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, NRx Pharmaceuticals, Inc. respectfully requests that the effective date of the above-referenced Registration Statement on Form S-3/A (the "Registration Statement") be accelerated so as to permit it to become effective at 5:00 p.m. Washington D.C. time on December 22, 2025, or as soon thereafter as practicable.

Please call Kevin J. Roggow of Cozen O'Connor at (212) 908-1294 to provide notice of the effectiveness of the Registration Statement.

\* \* \*

[*Signature Page Follows]*

------

---

| | |
|:---|:---|
| Very truly yours, | Very truly yours, |
| NRx Pharmaceuticals, Inc. | NRx Pharmaceuticals, Inc. |
| By: | /s/ Jonathan Javitt |
| Name: | Jonathan Javitt |
| Title: | Interim Chief Executive Officer |

---

cc: Kevin J. Roggow *Cozen O*'*Connor*

[*Signature Page to Acceleration Request Letter*]